glp-1 gip and glucagon receptor agonists are increasingly used to treat type 2 diabetes obesity, and trials have shown reductions in cardiovascular risk and slowing of kidney failure. Adverse events are mostly gastrointestinal 🧬 GLP-1. GIP. Glucagon. You've

Theyll help you understand and navigate your dosing and titration schedule, which theyll determine based on your health profile and bodys response

filing is expected in 2027

This reinforces the importance of looking beyond a single point-in-time measure, Poulopoulos said, noting that underwriters increasingly consider broader indicators of metabolic health and weight history rather than current BMI alone

In particular, diabetes-related hyperglycemia acts through oxidative stress, fibrosis and severe inflammation in the reproductive tract, as demonstrated by the increase in serum transforming growth factor beta (TGF-), malonylaldehyde (MDA), and pentraxin-3 (PTX-3), with reduction in ovarian reserve and antimullerian hormone (AMH)